Dexmedetomidine Upregulates MicroRNA-185 to Suppress Ovarian Cancer Growth Via Inhibiting the SOX9/Wnt/β-catenin Signaling Pathway

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2021 Apr 5

PMID 33818283

Citations 7

Authors

Hang Tian

Lei Hou

Yumei Xiong

Qiuju Cheng

Affiliations

Soon will be listed here.

Abstract

Dexmedetomidine (DEX) could serve as an adjuvant analgesic during cancer therapies. Abnormal expression of microRNAs (miRNAs) could lead to cancer development. This study was aimed to explore the roles of DEX in ovarian cancer (OC) development. OC cell lines SKOV3 and HO-8910 were treated with DEX, after which OC development and the miR-185, SOX9, and Wnt/β-catenin pathway were measured. DEX-treated HO-8910 cells were transfected with miR-185 mimic, miR-185 antisense or miR-185 antisense + silenced SOX9 to further measure the OC cell growth. The target relation between miR-185 and SOX9 was identified, and SOX9 and Wnt/β-catenin pathway were protein levels detected after miR-185 transfection. The role of miR-185 in OC was also measured. Our study found DEX had a dose-dependent inhibition on OC growth, and DEX promoted miR-185 but suppressed SOX9 expression in OC cells. miR-185 targeted SOX9. After interfering with miR-185 expression, HO-8910 cell proliferation, invasion, migration, and apoptosis were affected. SOX9 knockdown repressed OC development and Wnt/β-catenin pathway. The volume, weight, positive rate of Ki67, CyclinD1, p53 and the degree of tumor necrosis were affected by miR-185 expression. This study demonstrated that DEX could inhibit OC development via upregulating miR-185 expression and inactivating the SOX9/Wnt/β-catenin signaling pathway.

Citing Articles

Trial watch: dexmedetomidine in cancer therapy.

Carnet Le Provost K, Kepp O, Kroemer G, Bezu L Oncoimmunology. 2024; 13(1):2327143.

PMID: 38481729 PMC: 10936656. DOI: 10.1080/2162402X.2024.2327143.

Dexmedetomidine ameliorates liver injury and maintains liver function in patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study with propensity score matching.

Wang X, Li Y, Shi Y, Li X, Luo J, Zhang Y Front Oncol. 2023; 13:1108559.

PMID: 37152009 PMC: 10160666. DOI: 10.3389/fonc.2023.1108559.

Tumor Necrosis Factor Alpha: Implications of Anesthesia on Cancers.

Tseng W, Lai H, Huang Y, Chan S, Wu Z Cancers (Basel). 2023; 15(3).

PMID: 36765695 PMC: 9913216. DOI: 10.3390/cancers15030739.

Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials.

Xu W, Zheng Y, Suo Z, Fei K, Wang Y, Liu C Front Oncol. 2022; 12:970557.

PMID: 36185178 PMC: 9518820. DOI: 10.3389/fonc.2022.970557.

Emerging Trends on the Correlation Between Neurotransmitters and Tumor Progression in the Last 20 Years: A Bibliometric Analysis CiteSpace.

Shi Y, Luo J, Wang X, Zhang Y, Zhu H, Su D Front Oncol. 2022; 12:800499.

PMID: 35280754 PMC: 8907850. DOI: 10.3389/fonc.2022.800499.

References

Mohta M, Kalra B, Sethi A, Kaur N . Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery. J Anesth. 2015; 30(2):252-60. DOI: 10.1007/s00540-015-2123-8. View

Freitas M, Alves V, Sarmento-Ribeiro A, Mota-Pinto A . Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Biochem Biophys Res Commun. 2011; 408(4):713-9. DOI: 10.1016/j.bbrc.2011.04.109. View

Li Y, Liu J, Piao J, Ou J, Zhu X . Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA-105/SOX9/Wnt/β-catenin axis. IUBMB Life. 2020; 73(1):159-176. DOI: 10.1002/iub.2415. View

Endesfelder S, Makki H, Von Haefen C, Spies C, Buhrer C, Sifringer M . Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain. PLoS One. 2017; 12(2):e0171498. PMC: 5291450. DOI: 10.1371/journal.pone.0171498. View

Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G . Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017; 36(29):4089-4099. PMC: 5540148. DOI: 10.1038/onc.2017.11. View

Lei Z, Shi H, Li W, Yu D, Shen F, Yu X . miR‑185 inhibits non‑small cell lung cancer cell proliferation and invasion through targeting of SOX9 and regulation of Wnt signaling. Mol Med Rep. 2017; 17(1):1742-1752. PMC: 5780119. DOI: 10.3892/mmr.2017.8050. View

Liu C, Li G, Ren S, Su Z, Wang Y, Tian Y . miR-185-3p regulates the invasion and metastasis of nasopharyngeal carcinoma by targeting WNT2B . Oncol Lett. 2017; 13(4):2631-2636. PMC: 5403522. DOI: 10.3892/ol.2017.5778. View

Ma F, Ye H, He H, Gerrin S, Chen S, Tanenbaum B . SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016; 126(5):1745-58. PMC: 4855922. DOI: 10.1172/JCI78815. View

Abukiwan A, Nwaeburu C, Bauer N, Zhao Z, Liu L, Gladkich J . Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Int J Oncol. 2018; 54(1):53-64. PMC: 6255064. DOI: 10.3892/ijo.2018.4616. View

10.

Nikpayam E, Tasharrofi B, Sarrafzadeh S, Ghafouri-Fard S . The Role of Long Non-Coding RNAs in Ovarian Cancer. Iran Biomed J. 2016; 21(1):3-15. PMC: 5141251. DOI: 10.6091/.21.1.24. View

11.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

12.

Cai C, Wang H, He H, Chen S, He L, Ma F . ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013; 123(3):1109-22. PMC: 3582143. DOI: 10.1172/JCI66666. View

13.

Tian H, Hou L, Xiong Y, Cheng Q, Huang J . Effect of Dexmedetomidine-Mediated Insulin-Like Growth Factor 2 (IGF2) Signal Pathway on Immune Function and Invasion and Migration of Cancer Cells in Rats with Ovarian Cancer. Med Sci Monit. 2019; 25:4655-4664. PMC: 6604677. DOI: 10.12659/MSM.915503. View

14.

Wang X, Zhao B, Li X . Dexmedetomidine attenuates isoflurane-induced cognitive impairment through antioxidant, anti-inflammatory and anti-apoptosis in aging rat. Int J Clin Exp Med. 2016; 8(10):17281-8. PMC: 4694220. View

15.

Imam J, Buddavarapu K, Lee-Chang J, Ganapathy S, Camosy C, Chen Y . MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene. 2010; 29(35):4971-9. DOI: 10.1038/onc.2010.233. View

16.

Zhang Y, Jia S, Gao T, Zhang R, Liu Z, Wang Y . Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction. Immunobiology. 2017; 223(1):32-37. DOI: 10.1016/j.imbio.2017.10.017. View

17.

Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y . MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem. 2014; 392(1-2):153-9. DOI: 10.1007/s11010-014-2028-0. View

18.

Guo Y, Xie X, Fu J, Xing G . SOX9 regulated proliferation and apoptosis of human lung carcinoma cells by the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018; 22(15):4898-4907. DOI: 10.26355/eurrev_201808_15626. View

19.

Bareiss P, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U . SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013; 73(17):5544-55. DOI: 10.1158/0008-5472.CAN-12-4177. View

20.

Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L . High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol. 2011; 122(1):171-7. PMC: 3104081. DOI: 10.1016/j.ygyno.2011.03.002. View